Aktis Oncology, Inc. Cash and Cash Equivalents
Aktis Oncology, Inc. (AKTS) had Cash and Cash Equivalents of $82.49 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-13
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $82.49M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $371.63M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $37.78M.
- 2025-06-30: Cash and Cash Equivalents, at Carrying Value $110.22M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $82.49M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $371.63M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $37.78M 10-Q · filed 2026-08-13 |
| 2025-06-30 | $110.22M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $58.25M 10-Q · filed 2026-05-11 |